• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Switzerland·Healthcare·0RRB.L
Share

DocMorris AG Stocks

CHF 8.56Last Updated 10.07.2026

Issuer Rating

3/7
Performance

Favourable

Risk

High

Recommendation

Sell

Market Cap

CHF 510.01M

CHF 8.56
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Founded in 1993 and headquartered in Frauenfeld, Switzerland, DocMorris AG primarily manages digital pharmacies alongside a wholesale division specializing in pharmaceuticals and health-related merchandise, operating within Switzerland and across international markets. Its product portfolio encompasses both prescription-required and over-the-counter medications, and also includes consumer health products, beauty and personal care items, nutritional supplements, pain relievers, and first aid provisions. Furthermore, it offers medicine management services. Complementing its online activities, the company also runs physical pharmacy outlets. Sales are conducted directly to medical practitioners, through other online mail-order pharmacies, and to private individuals, under brands such as Zur Rose, PromoFarma, TeleClinic, and DocMorris. Known as Zur Rose Group AG until May 2023, the company subsequently rebranded as DocMorris AG.

Company Valuation

Greatly undervalued
7/7

Based on key historical and expected multiples, the stock is greatly undervalued relative to its peers.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

13.07.2026 16:55

Morgan Stanley Expects Earnings Growth Outside the Tech Sector. What to Buy Ahead of Earnings Season?

13.07.2026 16:34

Oninvest Index: Top AI Small-Caps for the First Half of the Year

13.07.2026 15:34

Morning in New York: External Factors Heighten Risks

13.07.2026 14:37

Shares of L’Oréal’s small-cap partner have surged. It will go private

13.07.2026 13:45

SK Hynix Shares Have Their Worst Day Ever After a Record-Breaking U.S. Debut. Is It Time to Buy?

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026